---
title: "Encompass Health targets $5.8B-$5.9B revenue in 2025 amid capacity expansion"
date: "2025-02-07 21:53:48"
summary: "Earnings Call Insights: Encompass Health Corporation (NYSE:EHC) Q4 2024 Management View CEO Mark Tarr emphasized strong financial performance in Q4 2024, with revenue increasing 12.7%, adjusted EBITDA rising 13.6%, and adjusted EPS growing 23.2%. Total discharge growth reached 7.8%, supported by broad-based strength across geographies and patient mix. The company..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Encompass Health Corporation (NYSE:[EHC](https://seekingalpha.com/symbol/EHC "Encompass Health Corporation")) Q4 2024

### Management View

* CEO Mark Tarr emphasized strong financial performance in Q4 2024, with revenue increasing 12.7%, adjusted EBITDA rising 13.6%, and adjusted EPS growing 23.2%. Total discharge growth reached 7.8%, supported by broad-based strength across geographies and patient mix.
* The company highlighted its focus on addressing the demand-supply imbalance for inpatient rehabilitation facilities (IRFs), with Medicare beneficiaries being a key driver of growth. Tarr noted the underserved market for IRF services and the company's ability to meet high-acuity patient needs.
* Tarr detailed capacity expansion efforts, including the addition of 427 new beds in 2024 and plans to open seven new de novo hospitals and one satellite hospital in 2025, along with 100 additional beds to existing hospitals. He emphasized the company’s strong presence in Florida, with five new hospitals planned in the state for 2025.
* CFO Douglas Coltharp reported Q4 revenue of $1.4 billion, supported by discharge growth of 7.8% and a 4.2% increase in net revenue per discharge. Medicare Advantage discharges grew 14.7%, while Medicare saw a 6.8% increase. Adjusted free cash flow surged 103.7% to $190.5 million in Q4.

### Outlook

* Encompass Health provided 2025 guidance for net operating revenue between $5.8 billion and $5.9 billion, adjusted EBITDA of $1.16 billion to $1.20 billion, and adjusted EPS of $4.67 to $4.96.
* The company expects continued capacity growth, with an emphasis on opening eight hospitals in 2025 and adding 340 beds through de novo projects and expansions. New facilities include five hospitals in Florida and one in Connecticut, marking expansion into a 38th state.
* Coltharp outlined expectations for elevated pre-opening and ramp-up costs, primarily in the latter half of 2025, linked to new hospital openings.

### Financial Results

* Revenue for Q4 2024 increased 12.7% to $1.4 billion, with adjusted EBITDA rising 13.6% to $289.6 million. Total discharge growth reached 7.8%, driven by Medicare Advantage discharges, which grew 14.7%.
* Net revenue per discharge was bolstered by a 200-basis-point decrease in bad debt expense, which now stands at 2.1%.
* Adjusted free cash flow for the full year reached $690 million, up 31.3% from 2023. The company’s net leverage decreased to 2.2x by year-end 2024.

### Q&A

* Whit Mayo, Leerink Partners, asked about Medicare Advantage growth trends. CFO Coltharp explained that growth was driven by both same-store increases and expansion into new markets. Medicare Advantage discharges grew 14.7% for the quarter, with a five-year CAGR of 11.6%.
* Matthew Gilmore, KeyBanc, inquired about the pace of bed additions in 2025. CEO Tarr noted the addition of one more hospital compared to 2024, alongside 100 new beds, reflecting the company’s ability to meet demand.
* Andrew Mok, Barclays, questioned group medical cost trends. Coltharp identified GLP-1 drugs, cancer treatments, and specific eye health medications as drivers of increased costs, which are expected to normalize in the second half of 2025.

### Sentiment Analysis

* Analysts highlighted enthusiasm for Medicare Advantage growth and capacity expansion but showed concern over group medical cost pressures and pre-opening expenses. Overall tone was slightly positive, with focus on sustained growth opportunities.
* Management maintained a confident tone during prepared remarks, emphasizing strategic execution and market leadership. However, responses to analyst questions about medical costs and regulatory trends included cautious language, such as "We expect" and "We are hopeful," reflecting some uncertainty.
* Compared to the previous quarter, both analysts and management showed similar confidence levels, with consistent focus on growth and operational improvements.

### Quarter-over-Quarter Comparison

* Revenue growth accelerated in Q4 2024 compared to Q3, with discharge growth of 7.8% versus 8.8% in the previous quarter. Medicare Advantage growth remained strong, increasing from 12.6% in Q3 to 14.7% in Q4.
* Management’s tone remained confident, with continued emphasis on capacity expansion and strategic execution.
* Analysts’ focus shifted slightly from hurricane-related disruptions in Q3 to broader trends in Medicare Advantage growth and cost management in Q4.

### Risks and Concerns

* Management cited elevated group medical costs, driven by high-cost specialty drugs, as a challenge that is expected to persist into the first half of 2025.
* Analysts raised concerns about pre-opening and ramp-up costs for new hospitals, as well as ongoing regulatory scrutiny of Medicare Advantage plans.
* Potential delays in construction and cost inflation remain risks, though management expressed confidence in mitigating these through prefabrication strategies and operational efficiencies.

### Final Takeaway

Encompass Health concluded 2024 with strong financial performance, driven by discharge growth and Medicare Advantage expansion. The company remains committed to addressing the underserved demand for IRF services through capacity expansion, with plans to open eight new facilities in 2025. While group medical costs and pre-opening expenses pose challenges, management’s strategic focus on growth and operational efficiency underscores its confidence in achieving 2025 guidance targets.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/EHC/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4405257-encompass-health-targets-5_8b-5_9b-revenue-in-2025-amid-capacity-expansion)
